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Abstract 
 
Recent studies have shown that reduced mitochondrial content and function in 
skeletal muscle are common features of type 2 diabetes. Here, we review the 
molecular mechanisms involved in the regulation of mitochondrial genes in 
skeletal muscle, focusing on a key transcriptional network consisting of ERR 
and PGC-1. We describe how knowledge of this transcriptional circuit may be 
translated to the development of novel therapies for type 2 diabetes. 
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Introduction 
 
Type 2 diabetes is a complex disease that stems from an interaction of 
environmental and genetic factors. Hallmarks of the disease are insulin 
resistance in skeletal muscle, liver, and fat, combined with relative insulin 
insufficiency due to a decline in -cell function. Moreover, intracellular triglyceride 
accumulation in muscle and liver has also been associated with the disease [1]. 
Recently, genome-wide expression analysis revealed that mitochondrial oxidative 
phosphorylation (OXPHOS) genes exhibit reduced expression in pre-diabetic and 
diabetic individuals when compared to healthy controls [2,3], and that these 
genes are downstream of the transcriptional co-activator PGC-1 [2]. These 
genes also show reduced expression in the healthy individuals with a family 
history of diabetes [2,3]. Consistent with these findings, several reports have 
shown that diabetics as well as individuals with a family history of diabetes have 
reduced OXPHOS capacity in muscle [4]. At present, whether reduced OXPHOS 
gene expression is simply a correlate of diabetes or actually causal in this 
common disorder is not known. 
Together, these recent findings motivate the tantalizing hypothesis that drugs 
that boost OXPHOS capacity in muscle may improve diabetes. Accordingly, it 
has long been known that aerobic exercise, which is one of the best non-
pharmacologic interventions for ameliorating diabetes, increases mitochondrial 
content and promotes OXPHOS gene expression. While attractive, these studies 
did not provide a druggable target for modulating mitochondrial OXPHOS 
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capacity. Recently, we discovered that the nuclear receptor ERR is recruited by 
PGC-1 to regulate the OXPHOS transcriptional program that is altered in 
diabetic muscle [5]. Knowledge of this transcriptional circuit provides a new 
opportunity to modulate the mitochondrion for treating diabetes. 
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Strategies for targeting ERR and PGC-1 to promote OXPHOS 
 
ERR is a member of the nuclear receptor superfamily. Nuclear receptors are 
modular proteins with distinct DNA-binding, activation, and ligand-binding 
domains. The tertiary structure of the ligand-binding domain often permits binding 
of full and partial agonists, antagonists and inverse agonists. These proteins are 
located either in the cytoplasm or the nucleus and thus, their ligands are often 
small and lipophilic. Nuclear receptors are attractive drug targets because of 
these special properties [6]. 
ERR binds to an individual or repeats of extended half-sites (usually 6-9 
basepairs long) in the promoter of target genes, either as a monomer or as a 
homodimer, respectively [7,8]. ERR is thought to be involved in bone formation, 
aromatase and lactoferrin expression in estrogen-responsive tissues, as well as 
mitochondrial fatty acid -oxidation in skeletal muscle and the heart [7,8]. 
Relatively little was known about the roles for ERR (NR3B1) or its two closely 
related family members ERR (NR3B2) or ERR (NR3B3) in vivo. 
Recently, the discovery of the interaction between ERR and the transcriptional 
co-activator PGC-1 led to a breakthrough in understanding the function of 
ERR [5,9-11]. PGC-1 is a key regulator of mitochondrial biogenesis and 
oxidative metabolism in different tissues [12]. An unbiased, global screen 
revealed that PGC-1 regulates many mitochondrial OXPHOS genes via its 
interaction with ERR and the GA-binding protein A (GABPA, alternatively called 
nuclear respiratory factor 2a or NRF-2a), as depicted in Figure 1 [5]. Binding 
- 7 - 
sites for ERR in the promoter of PGC-1 target genes are the highest scoring 
motifs on day 1, day 2 and day 3 after adenoviral PGC-1 infection of mouse 
myotubes as found by motifADE, a computer algorithm that combined gene 
expression data with promoter analysis [5]. Among the genes regulated by PGC-
1 and ERR are those found to be decreased in skeletal muscle of type 2 
diabetic patients [2,3]. 
Less is known about the role for GABPA in this process; this review will thus 
focus on the physiological significance of the interaction between PGC-1 and 
ERR. In the next few sections, we discuss strategies for promoting 
mitochondrial biogenesis and OXPHOS activity through targeting ERR alone, 
PGC-1 alone, or through promoting interactions between both proteins. 
 
Direct targeting of ERR 
ERR is a very early PGC-1 target gene and thus a major regulator of 
OXPHOS and fatty acid oxidation gene expression. In cultured myotubes, 
adenoviral infection with PGC-1 elevates ERR expression on day 1 post 
infection [5]. Moreover, ERR binding motifs are located in the promoter regions 
of early and late PGC-1 target genes, including ERR itself and GABPA [5]. 
While additional transcription factors downstream of ERR could also be 
considered as targets for modulating mitochondrial OXPHOS, these factors alone 
will likely not be sufficient in stimulating the entire transcriptional program 
involved in mitochondrial biogenesis. Those include the nuclear respiratory factor 
1 (NRF-1), the nuclear respiratory factor 2 (which is the GABPA/B heterodimer) 
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involved in mitochondrial biogenesis [5,13] or the peroxisome proliferator-
activated receptor  (PPAR, NR1C1), which is a target of fibrate drugs and 
regulates mitochondrial fatty acid -oxidation [14]. 
 
ERR controls its own transcription by an autoregulatory loop [5,15]. 
Interestingly, ERR binding sites in the ERR promoter are polymorphic in their 
copy number [15]. Increased number of ERR binding motifs results in elevated 
activation of ERR transcription by ERR and PGC-1. It remains to be shown 
whether this copy number polymorphism confers risk to the development of type 
2 diabetes. Thus, as a nuclear receptor, targeting of ERR with small molecules 
is an attractive strategy to increase mitochondrial OXPHOS function in diabetic 
patients. In principle, such a small molecule may activate the double-positive 
feedback loop between GABPA and ERR shown in Figure 1, hence stimulating 
the entire transcriptional cascade involved in mitochondrial biogenesis. 
Moreover, since ERR is involved in the regulation of fatty acid -oxidation, 
activating ERR may ameliorate the lipid accumulation in skeletal muscle, which 
is believed to contribute to insulin resistance. 
 
Caveat: Transcriptional activity of ERR is dependent on cellular context [16]. 
Under some circumstances, the ability of ERR to drive transcription of target 
genes is very low whereas in other cells, this receptor has high constitutive 
activity. Thus, cell-dependent transcriptional activity could reflect the presence of 
context-specific transcriptional co-activators, signaling cascades or endogenous 
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ligands. The crystal structure of the ERR ligand-binding domain together with a 
co-activator peptide derived from PGC-1 revealed a transcriptionally active 
conformation even in the absence of a ligand [17]. In addition, the ligand-binding 
pocket of ERR is very small in comparison to other nuclear receptors [17]. Due 
to the steric limitations and the conformation of the ligand-binding domain, it is 
not clear whether it is possible to further activate ERR with synthetic agonists. 
However, it is encouraging that several synthetic compounds have been found to 
repress the activity of ERR, indicating that, in principle, this receptor can be 
pharmacologically targeted. 
The physiological role of ERR is not restricted to its metabolic functions in 
skeletal muscle. While activation of ERR in skeletal muscle may ameliorate 
diabetes and may improve osteoporosis in bone [18], it may have undesirable 
consequences in mammary tissue, since ERR is a biomarker for poor outcome 
in human breast cancer [19]. Paradoxically, ERR knockout animals are lean 
and resistant to a high fat diet [20], in contrast to what was expected from the 
data linking ERR to OXPHOS and fatty acid oxidation. Because of the tight 
functional interaction between ERR and PGC-1 and the complex expression 
pattern of ERR in the central nervous system, it is conceivable that the ERR -/- 
mice have a similar brain phenotype as observed in the lean, hyperactive PGC-
1 knockouts [21]. Another explanation for the lean phenotype is reduced 
apolipoprotein expression in the intestine and a subsequent defect in fat 
absorption in the ERR knockout mice [22]. In this case, selective inhibition of 
ERR in the intestine, where ERR is highly expressed, might be an interesting 
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approach in both obesity and diabetes. Future work should thus aim at providing 
a more comprehensive understanding of the physiological role of ERR in 
different tissues and how those could be specifically targeted by pharmacological 
means. 
 
Increasing PGC-1 activity 
 
The transcriptional co-activator PGC-1 is a master regulator of mitochondrial 
biogenesis and oxidative metabolism [12]. Moreover, PGC-1 increases 
expression of the insulin-sensitive glucose transporter GLUT4 and promotes 
muscle fiber-type switching from type 2b towards the more oxidative type 2a and 
type 1 muscle fibers [23,24]. Expression of PGC-1 is decreased in skeletal 
muscle of type 2 diabetic patients concomitant with the observed defects in 
mitochondrial function [2,3]; thus, increasing PGC-1 activity could potentially 
counter the deleterious effects observed in diabetes. Intriguingly, exercise 
combined with changes in lifestyle is one of the most potent interventions for the 
prevention and treatment of type 2 diabetes [25]. It is thought that many of the 
beneficial effects of physical activity are due to induction of PGC-1 levels by 
exercise. 
 
PGC-1 activity is regulated at multiple levels: first, since the half-life of the PGC-
1 protein is relatively short [26], its levels are rapidly adjusted by transcriptional 
control. Exercise-induced calcium signaling potently induces PGC-1 
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transcription in skeletal muscle [27,28]. Modulation of this pathway or of the 
transcription factors involved (calcium/calmodulin-dependent protein kinase IV, 
calcineurin A, myocyte enhancer factor 2) may elevate PGC-1 levels. Second, 
posttranslational modifications can both stabilize the PGC-1 protein as well as 
control its interaction with inhibitory (p160 myb binding protein, histone 
deacetylase 5) and activating protein complexes (histone acetyltransferases, the 
TRAP/mediator complex and sirtuin 1/SIRT1) [26,28-32]. As a transcriptional co-
activator, PGC-1 has neither a DNA-binding domain nor a ligand-binding 
domain. Moreover, it is not known to have enzymatic activity, making it difficult to 
target pharmacologically. These obstacles may be overcome by modulating the 
activity of PGC-1 binding partners, e.g. by using histone deacetylase inhibitors. 
Finally, it might be possible to target the upstream signaling pathways that result 
in PGC-1 phosphorylation and deacetylation and subsequent change in activity 
[26,29]. 
 
Caveat: PGC-1 is expressed in a variety of different tissues. While increasing 
adaptive thermogenesis in brown fat or OXPHOS capacity in muscle via PGC-1 
could help obese and diabetic individuals, increasing PGC-1 activity in all 
tissues of type 2 diabetic patients could have untoward side-effects. For 
example, PGC-1 is a strong regulator of hepatic gluconeogenesis and 
accordingly, PGC-1 levels are elevated in the liver of animal models of type 1 
and type 2 diabetes [33]. Similarly, PGC-1 inhibits insulin secretion in 
pancreatic -cells [34] and thus PGC-1 activity in these two tissues should be 
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reduced in diabetes. In the heart, PGC-1 is involved in the switch in fuel 
utilization during development [35] and may also play a role in mediating 
cardiomyopathy and heart failure, though this is currently still under debate 
[35,36]. On the other hand, PGC-1 and its target genes are reduced in different 
animal models and patients with heart failure and this dysregulation might 
contribute to the pathological remodeling in cardiac muscle [35,36]. The function 
of PGC-1 in other tissues (e.g. kidney, brain) has yet to be more thoroughly 
explored before a conclusive statement can be given about the effect of PGC-1 
modulation in those tissues. Hence, direct targeting of PGC-1 could have 
numerous undesired side-effects in other tissues. 
 
Targeting the ERR-PGC-1 interaction 
 
Perhaps the most promising and most specific strategy to boost OXPHOS would 
involve targeting the PGC-1/ERR interaction (Figure 1). Some of the known 
synthetic inhibitors of nuclear receptors work by interfering with the binding of co-
activators – for example, toxaphene and chlordane reduce binding of the 
glucocorticoid receptor-interacting protein 1 (GRIP1) [37]. Recently, the inverse 
agonist XCT790 was shown to reduce the interaction between ERR and PGC-
1 [5,38]. By inhibiting PGC-1 binding to ERR with XCT790, skeletal muscle 
cellular respiration and expression of OXPHOS genes were reduced [5]. This 
ERR inverse agonist thus elicited a “diabetic” phenotype in these cells. Other 
PGC-1 target genes were unaffected by treatment with XCT790 in muscle and 
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in liver, respectively. Importantly, XCT790 did not inhibit PGC-1-driven hepatic 
gluconeogenic gene expression [5]. Therefore, in principle, synthetic compounds 
that enhance PGC-1-ERR interactions ought to selectively improve the 
aberrant OXPHOS gene expression in skeletal muscle while not modulating 
ERR-independent functions of PGC-1 or PGC-1-independent functions of 
ERR. Hence, this strategy may confer the needed specificity to avoid the 
deleterious effects of modulating these proteins in other tissues, which, as 
discussed previously, could exacerbate diabetes. 
 
Caveat: ERR has so far only been targeted with inhibitory synthetic 
compounds. It is unclear whether the PGC-1-ERR binding can be promoted 
since PGC-1 might not require a conformational change in the ERR structure 
for optimal binding. In that case, PGC-1-dependent ERR activity may be 
exclusively regulated by relative levels of PGC-1 in a specific tissue and 
context. Compounds that mimic PGC-1 binding to ERR could circumvent that 
scenario. 
 
Conclusions 
 
At present, a wealth of clinical and basic biological studies support the notion that 
inherited or acquired variation in mitochondria can contribute to the development 
of type 2 diabetes (summarized in ref. [4]). First, genome-wide expression 
analyses have suggested that the muscle of diabetics, as well as prediabetics 
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and individuals with a family history of diabetes, have reduced expression of 
mitochondrial OXPHOS genes. Second, functional studies have shown that 
diabetics and prediabetics have lower ATP production capacity in muscle. Third, 
functional and histological studies of skeletal muscle mitochondria from diabetic 
patients have revealed smaller mitochondria with reduced enzymatic capacities 
than those in healthy volunteers. Fourth, there appears to be reduced oxidative 
phosphorylation activity in elderly, insulin-resistant individuals as compared to a 
younger control group. Moreover, a Gly482Ser single nucleotide polymorphism in 
the PGC-1 gene was found to be associated with type 2 diabetes in some 
populations [39], as well as with cardiovascular adaptation following physical 
exercise [40]. Thus, reduced OXPHOS and PGC-1 levels might be causally 
linked to the development of the disease. 
 
ERR and PGC-1 each are members of a small family of related genes. 
Whereas expression of ERR in postnatal development is restricted and only low 
levels are detected in liver, stomach, skeletal muscle, heart and kidney, ERR is 
widely expressed in adult tissues [7,8]. ERR is co-activated by PGC-1 and thus 
could have similar importance as a drug target. Unfortunately, ERR ligand-
binding domain crystal structures revealed a ligand-independent active 
conformation [41]. Therefore, finding ligands for ERR suffers from the same 
limitations as with ERR. PGC-1 has a similar expression pattern as PGC-1 
[12]. These two proteins have distinct as well as overlapping functions, both 
being strong activators of mitochondrial biogenesis and oxidative metabolism. In 
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addition, like PGC-1, PGC-1 levels are reduced in skeletal muscle of 
prediabetic and diabetic patients [3]. Thus, the potential of PGC-1 for the 
treatment of type 2 diabetes remains to be investigated. Probably less interesting 
in this regard, the PGC-1-related co-activator (PRC) is expressed ubiquitously 
and is not subject to the same regulatory mechanisms as PGC-1 and PGC-1 
[12]. 
 
Mitochondrial biogenesis and oxidative metabolism are fundamental processes 
resident in virtually all cells; therefore, therapeutic strategies involving this 
organelle must consider tissue specific differences in mitochondria [42]. Similarly, 
tissue-selective targeting the ERR-PGC-1 axis in skeletal muscle is an 
attractive approach to treat the mitochondrial dysfunctions that have been 
associated with type 2 diabetes with the caveats in other tissues as described 
above [4,40,43]. 
 
Worldwide, type 2 diabetes is on a steep rise as a result of an aging population 
as well as by obesity and a sedentary lifestyle [1]. Diabetes and related disorders 
are the fifth leading cause of death in the United States. This not only has 
implications for affected patients, but also places a tremendous financial burden 
on the healthcare system. At present, only a handful of drugs, in combination 
with diet and exercise, are useful in delaying the onset of diabetes and its 
complications. Recent discoveries suggest that the mitochondrion may be central 
in the pathogenesis of type 2 diabetes; these studies motivate the idea that 
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targeting this organelle may ameliorate diabetes. Augmenting mitochondrial 
mass and function via pharmacologic manipulation of ERR/PGC-1 may 
represent a fundamentally new approach to treating and preventing this growing 
epidemic. It might even be possible that this pathway has broader implication in 
the metabolic syndrome; however, association of the ERR-specified PGC-1 
target gene expression with cardiovascular disease or stroke remains to be 
shown. 
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Outstanding issues 
 
 Is it possible to design ERR agonists? 
 Can the ERR-PGC-1 protein-protein interaction be enhanced with 
synthetic compounds? 
 What are the roles for other ERR (ERR, ERR) and PGC-1 (PGC-1, 
PRC) family members? 
 What are the potential side effects (in other tissues) that would arise from 
the various proposed strategies affect? 
 
Related links 
 
 www.niddk.nih.gov (National Institute of Diabetes & Digestive & Kidney 
Diseases) 
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 www.cdc.gov/diabetes (Center for Disease Control Diabetes Public Health 
Resource) 
 www.diabetes.org (American Diabetes Association) 
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Table 1. Different approaches to improve mitochondrial function in type 2 diabetes. 
 Pros Cons Latest 
developments
Who is working 
on this strategy?
Relevant patents References 
ERRa agonists Nuclear receptor: good 
drug target 
Tissue selectivity; 
feasibility of designing 
an agonist 
  WO 00/47735, WO 
05/003766 
[17] 
PGC-1a 
activators 
Signaling pathways and 
proteins modulating PGC-
1 function in skeletal 
muscle are well described 
Tissue selectivity   WO 02/062297, WO 
00/32215, WO 01/90356, 
WO 01/35096 
[40,43] 
Modulation of 
ERRa-PGC-1a 
binding 
Specific targeting of 
protein-protein interaction 
might circumvent adverse 
effects in other tissues 
Feasibility of targeting 
a protein-protein 
interaction 
  WO 00/47735, WO 
02/062297, WO 
00/32215, WO 01/90356, 
WO 01/35096 
[5,11,38] 
aAbbreviations: ERR, estrogen-related receptor ; PGC-1, peroxisome proliferator-activated receptor  co-activator 1 
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Figure Legends 
 
Figure 1. Regulatory cascade in the expression of oxidative phosphorylation 
(OXPHOS) genes in skeletal muscle. Peroxisome proliferator-activated receptor  
co-activator 1 (PGC-1) levels in muscle are induced by physical exercise and 
reduced in type 2 diabetes. First, PGC-1 expression is controlled by a positive 
autoregulatory loop. The estrogen-related receptor  (ERR) and the GA-binding 
protein A (GABPA, alternatively called nuclear respiratory factor 2a, NRF2a) are 
early PGC-1 target genes. They regulate their own transcription and 
transcription of each other, both being co-activated by PGC-1. ERR and 
GABP (heterodimer of GABPA and GABPB) are the main docking partners for 
PGC-1 in the transcriptional cascade of later target genes that leads to 
increased OXPHOS and fatty acid -oxidation. For details, see refs. [5,27]. 
Abbreviations: CREB, cyclic AMP responsive element binding protein; MEF2, 
myocyte enhancer factor 2; NRF-1, nuclear respiratory factor 1. 
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